Jan Škoda
banner
skodalab.bsky.social
Jan Škoda
@skodalab.bsky.social
Group Leader, Laboratory of Tumor Biology, #MUNI & Laboratory Oncology Translational Research, #FNUSA-ICRC | Assoc. Prof. #MUNI, Brno, Czech Republic
Právě jsme s @lucieskodova.bsky.social shlédli - skvělé to bylo! 👏 Díky všem, co foukají do balónku 😉 @chmee2.bsky.social
February 9, 2025 at 10:29 PM
Very cool study, congrats!
January 23, 2025 at 7:29 PM
A tremendous effort by the first author Lucie Curylova! 👏 Huge thanks to my team @MUNI @FNUSA-ICRC and all collaborators @FNBrno @CEITEC_MUNI. Funded by
#AZVČR (Czech Health Research Council), with institutional support from the National Institute for Cancer Research & the Ministry of Health 🙏
January 23, 2025 at 4:46 PM
Finally, as all patient-derived models were wild-type p53, our findings suggest that restoring p53 function could offer a promising strategy for treating refractory/metastatic p53-overexpressing pediatric sarcomas, regardless of their TP53 mutational status.
January 23, 2025 at 4:46 PM
We tested this using paired models with different stemness levels. Our study shows for the first time that reactivating p53 signaling via MDM2/MDMX inhibition selectively induces cell death in aggressive, stem-like Ewing's sarcoma cells while sparing healthy fibroblasts.
January 23, 2025 at 4:46 PM
Indeed, SOX2 was detected only in human Ewing‘s sarcoma samples that overexpressed p53, indicating disruption of the p53 pathway. Moreover, altered p53 expression was prevalent in metastatic tumors, suggesting p53 as a clinically relevant target for reactivation therapies.
January 23, 2025 at 4:46 PM
Only cells with high SOX2 or KLF4 expression, along with p53 dysregulation, formed tumors in mice. SOX2 knockdown on a mutant p53 background reduced, but didn’t prevent self-renewal, suggesting p53 dysregulation is crucial for sarcoma cells to acquire a fully stem-like phenotype.
January 23, 2025 at 4:46 PM
Using a large panel of pediatric sarcoma models, in vivo assays, and tumor tissues, our study provides strong evidence that dysregulated p53 associates with the upregulation of stemness-related transcription factors and enhanced tumorigenicity in pediatric sarcoma cells.
January 23, 2025 at 4:46 PM
Pediatric sarcomas are bone & soft tissue tumors that often metastasize and show therapy-resistant cancer stem cell traits, making treatment challenging. An impaired p53 pathway is common in aggressive sarcomas, yet its link to sarcoma stemness has been unclear.
January 23, 2025 at 4:46 PM